Science Explorer Back to mapMap

Most cited papers from Hospices Civils de Lyon

What are the most cited papers from Hospices Civils de Lyon?

The most cited paper from Hospices Civils de Lyon is "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria" (Alan J. Thompson et al., 2017), with 8,265 citations. Next come "The 2016 revision of the World Health Organization classification of lymphoid neoplasms" (7,935) and "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer" (7,927).

Showing 50 of 60 papers. Every paper with more than 1,587 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria Alan J. Thompson et al. · The Lancet Neurology Open access 21 Dec 2017 8,265
2 The 2016 revision of the World Health Organization classification of lymphoid neoplasms Steven H. Swerdlow, Elı́as Campo, Stefano Aldo Pileri et al. · Blood Open access 15 Mar 2016 7,935
3 FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine Open access 11 May 2011 7,927
4 Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Richard S. Finn et al. · New England Journal of Medicine Open access 13 May 2020 7,547
5 ILAE Official Report: A practical clinical definition of epilepsy Robert S. Fisher, Carlos Alberto Acevedo, Alexis A. Arzimanoglou et al. · Epilepsia Open access Apr 2014 6,110
6 CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma Bertrand Coiffier, Éric Lepage, Josette Brière et al. · New England Journal of Medicine Open access 24 Jan 2002 5,630
7 EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection Pietro Lampertico, Kosh Agarwal, Thomas Berg et al. · Journal of Hepatology 18 Apr 2017 5,528
8 Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies Patrick Kwan, Alexis A. Arzimanoglou, Anne T. Berg et al. · Epilepsia 3 Nov 2009 4,888
9 Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis Luca Richeldi et al. · New England Journal of Medicine Open access 18 May 2014 4,731
10 Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Caroline Robert et al. · New England Journal of Medicine 5 Jun 2011 4,523
11 Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma Stephen J. Schuster et al. · New England Journal of Medicine Open access Dec 2018 4,157
12 Prone Positioning in Severe Acute Respiratory Distress Syndrome Claude Guérin et al. · New England Journal of Medicine Open access 20 May 2013 4,142
13 The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms Rita Alaggio et al. · Leukemia Open access 22 Jun 2022 4,010
14 Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Jordi Bruix et al. · The Lancet Open access 5 Dec 2016 3,732
15 FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 Ronald Boellaard et al. · European Journal of Nuclear Medicine and Molecular Imaging Open access Dec 2014 3,406
16 EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent Nicolas Mottet et al. · European Urology Open access 31 Aug 2016 3,282
17 DNA methylation-based classification of central nervous system tumours David Capper et al. · Nature Open access143 authors 13 Mar 2018 3,228
18 MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis Veeru Kasivisvanathan et al. · New England Journal of Medicine Open access 19 Mar 2018 3,101
19 Vitamin D 3 and Calcium to Prevent Hip Fractures in Elderly Women M C Chapuy, M Arlot, F. Duboeuf et al. · New England Journal of Medicine Open access 3 Dec 1992 2,969
20 Autoantibodies against type I IFNs in patients with life-threatening COVID-19 Paul Bastard et al. · Science Open access752 authors 24 Sep 2020 2,885
21 Everolimus for Advanced Pancreatic Neuroendocrine Tumors James C. Yao, Manisha H. Shah, Tetsuhide Ito et al. · New England Journal of Medicine Open access 9 Feb 2011 2,877
22 EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent Nicolas Mottet et al. · European Urology Open access 7 Nov 2020 2,876
23 Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion Victoria Campuzano et al. · Science 8 Mar 1996 2,812
24 Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy Richard S. Hotchkiss, Guillaume Monneret, Didier M. Payen · Nature reviews. Immunology ReviewOpen access 15 Nov 2013 2,777
25 Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Jeffrey S. Weber et al. · The Lancet Oncology 23 Mar 2015 2,696
26 Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul et al. · New England Journal of Medicine 9 Feb 2011 2,567
27 Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome Laurent Papazian, Jean-Marie Forel, Arnaud Gacouin et al. · New England Journal of Medicine Open access 15 Sep 2010 2,470
28 Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma Thierry O. Philip, Cesare Guglielmi, Anton Hagenbeek et al. · New England Journal of Medicine 7 Dec 1995 2,458
29 ESUR prostate MR guidelines 2012 Jelle O. Barentsz, Jonathan Richenberg, Richard Clements et al. · European Radiology Open access 9 Feb 2012 2,452
30 Nintedanib in Progressive Fibrosing Interstitial Lung Diseases Kevin R. Flaherty, Athol Umfrey Wells, Vincent Cottin et al. · New England Journal of Medicine Open access 29 Sep 2019 2,440
31 High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure J. P. Frat et al. · New England Journal of Medicine Open access 17 May 2015 2,419
32 Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018) Jean‐Pascal Lefaucheur et al. · Clinical Neurophysiology Open access 31 Dec 2019 2,413
33 Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma Ghassan K. Abou‐Alfa et al. · New England Journal of Medicine Open access 4 Jul 2018 2,386
34 Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer Antonio González-Martı́n et al. · New England Journal of Medicine Open access 28 Sep 2019 2,318
35 Strategies and challenges for the next generation of antibody–drug conjugates Alain Beck, Liliane Goetsch, Charles Dumontet et al. · Nature Reviews Drug Discovery Review 17 Mar 2017 2,280
36 Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma Jeffrey S. Weber et al. · New England Journal of Medicine Open access 10 Sep 2017 2,249
37 Development and Validation of the International Knee Documentation Committee Subjective Knee Form James J. Irrgang, Allen F. Anderson, Arthur L. Boland et al. · The American Journal of Sports Medicine Sep 2001 2,193
38 Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) Jean‐Pascal Lefaucheur et al. · Clinical Neurophysiology Open access 5 Jun 2014 2,178
39 Factors of patellar instability: An anatomic radiographic study H Dejour, Gilles Walch, Laurent Nové-Josserand et al. · Knee Surgery Sports Traumatology Arthroscopy Mar 1994 2,058
40 Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis You Li et al. · The Lancet Open access121 authors May 2022 2,013
41 Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force Gabor Abellán van Kan, Yves Rolland, Sandrine Andrieu et al. · The journal of nutrition health & aging Open access Dec 2009 2,013
42 A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic kidney disease Denis P. Fouque, Kamyar Kalantar‐Zadeh, Joel D. Kopple et al. · Kidney International Open access 19 Dec 2007 2,009
43 Effect of Risedronate on the Risk of Hip Fracture in Elderly Women Michael R. McClung, Piet Geusens, Paul D. Miller et al. · New England Journal of Medicine Open access Feb 2001 1,931
44 Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma Alexander M.M. Eggermont et al. · New England Journal of Medicine Open access 15 Apr 2018 1,906
45 Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS) Jean‐Pascal Lefaucheur et al. · Clinical Neurophysiology Open access 28 Oct 2016 1,878
46 Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation Jean‐François Obadia et al. · New England Journal of Medicine 27 Aug 2018 1,797
47 AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant Mice Li Yu, Shanqin Xu, Maria M. Mihaylova et al. · Cell Metabolism Open access Apr 2011 1,787
48 Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda et al. · Journal of Hepatology Open access 11 Dec 2021 1,749
49 Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia Richard R. Furman et al. · New England Journal of Medicine Open access 22 Jan 2014 1,706
50 Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial Andrew Xiuxuan Zhu et al. · The Lancet Oncology 18 Jan 2019 1,680

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.